Posted by Michael Wonder on 03 Aug 2023
Aardvark Therapeutics announces receipt of FDA rare paediatric disease designation for Prader-Willi syndrome
3 August 2023 - Aardvark's Phase 2 trial of oral ARD-101 in young adults with Prader-Willi syndrome is now open for enrolment of additional subjects.
Aardvark Therapeutics today reported receipt of a rare paediatric disease designation in Prader-Willi syndrome from the FDA for its lead program ARD-101.
